Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4K7GQ)

• Drug Name: Erythromycin Drug Info
• Synonyms: Abboticin; Abomacetin; Acneryne; Acnesol; Aknemycin; Aknin; AustriaS; Benzamycin; Derimer; Deripil; Dotycin; Dumotrycin; ERY; ERYC; Emgel; Emuvin; Emycin; Endoeritrin; Erecin; Erisone; Eritomicina; Eritrocina; Eritromicina; Ermycin; Eros; Eryacne; Eryacnen; Erycen; Erycette; Erycin; Erycinum; Eryderm; Erydermer; Erygel; Eryhexal; Erymax; Erymed; Erysafe; Erytab; Erythro; Erythroderm; Erythrogran; Erythroguent; Erythromid; Erythromycine; Erythromycinum; Erytop; Erytrociclin; Ilocaps; Iloticina; Ilotycin; Inderm; IndermRetcin; Latotryd; Lederpax; Mephamycin; Mercina; Oftamolets; Paediathrocin; Pantoderm; Pantodrin; Pantomicina; Pharyngocin; Primacine; Propiocine; Proterytrin; Retcin; Robimycin; Romycin; Sansac; Staticin; Stiemicyn; Stiemycin; Tiloryth; Tiprocin; Torlamicina; Wemid; Akne Cordes Losung; Aknederm Ery Gel; Benzamycin Pak; ERYTHROMYCIN STEARATE; Eryc Sprinkles; Erythromycin A; Erythromycin Lactate; Erythromycin Ointment; Erythromycin base; Erythromycin intravenous; Erythromycin sodium lauryl sulfate; Inderm Gel; Oftalmolosa Cusi Eritromicina; Skid Gel E; Theramycin Z; Udima Ery Gel; E0751; Eryc 125; Erythromast 36; Ak-Mycin; Akne-Mycin; Del-Mycin; E-Base; E-Glades; E-Mycin; E-Solve 2; ERYC (base); Emu-V; Emu-Ve; Erimycin-T; Eritromicina [INN-Spanish]; Ery-B; Ery-Diolan; Ery-Sol; Ery-Tab; Ery-maxin; Eryc (TN); Eryc-125; Eryc-250; Erygel (TN); Erythra-Derm; Erythro-Statin; Erythro-Teva; Erythromycin & VRC3375; Erythromycine [INN-French]; Erythromycinum [INN-Latin]; Ilosone (TN); Ilosone (estolate); Ilotycin T.S; Kesso-Mycin; N-Methylerythromycin A; PCE Dispertab (base); Pce (TN); R-P Mycin; Sans-acne; Staticin (TN); T-Stat; Taimoxin-F; A/T/S; Akne-mycin (TN); C-Solve-2; E-Base (base); E-Mycin (base); Ery-Tab (base); Erythromycin [INN:BAN:JAN]; Ilotycin T.S.; T-stat (TN); E-mycin, Erycin, Robimysin; Erythromycin (JP15/USP/INN); Erythromycin, compd. with monododecyl sulfate, sodium salt; Sulfuric acid, monododecyl ester, sodium salt, compd. with erythromycin; Adecane-2,10-dione (non-preferred name); Erythromycin A, T-Stat, Pantomicina, HSDB 3074, Erytab, DRG-0279; Ery

Indication

Disease Entry	ICD 11	Status	REF
Acne vulgaris	ED80	Approved	[1]
Acute gonococcal cervicitis		Approved	[1]
Acute otitis media	AB00	Approved	[1]
Bacteremia	1A73	Approved	[1]
Bacterial infection	1A00-1C4Z	Approved	[2]
Cholangitis		Approved	[1]
Gastroparesis	DA41.00	Approved	[1]
Hepatic coma		Approved	[1]
Inclusion conjunctivitis		Approved	[1]
Legionnaires' disease		Approved	[1]
Listeriosis		Approved	[1]
Mycoplasma pneumoniae pneumonia		Approved	[1]
Preterm premature rupture of the membranes		Approved	[1]
Staphylococcus aureus infection		Approved	[1]
Streptococcal pneumonia		Approved	[1]
Syphilis		Approved	[1]
Urinary tract infection	GC08	Approved	[1]
Erythema	ME64.0	Investigative	[1]
Pneumonia caused by chlamydia		Investigative	[1]

• Therapeutic Class: Antibiotics
• Cross-matching ID:
  PubChem CID: 12560
  ChEBI ID: CHEMBL532
  CAS Number: CAS 114-07-8
  TTD Drug ID: DM4K7GQ
  VARIDT Drug ID: DR00050
  INTEDE Drug ID: DR0614
  ACDINA Drug ID: D00241

Molecule-Related Drug Atlas

Drug(s) Targeting Bacterial 50S ribosomal RNA (Bact 50S rRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Telithromycin	DMZ4P3A	Bacterial infection	1A00-1C4Z	Approved	[23]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[24]
Dirithromycin	DM0D9YJ	Bacterial infection	1A00-1C4Z	Approved	[25]
Clindamycin	DM15HL8	Acne vulgaris	ED80	Approved	[24]
Zithromax	DMN4H2O	Syphilis infection	1A6Z	Approved	[26]
Troleandomycin	DMUZNIG	Bacterial infection	1A00-1C4Z	Approved	[27]
Retapamulin	DM9JXB7	Impetigo	1B72	Approved	[28]
Dalfopristin	DM4LTKV	Bacterial infection	1A00-1C4Z	Approved	[29]
Tedizolid	DMG2SKR	Skin infection	1F28-1G0Z	Approved	[30]
Gentamicine sulfate	DMBT7MI	Bacterial infection	1A00-1C4Z	Approved	[31]

Drug(s) Transported By Multidrug resistance-associated protein 2 (ABCC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[32]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[33]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[34]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[35]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[36]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[37]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[38]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[39]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[40]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[41]

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[42]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[43]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[44]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[45]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[44]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[44]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[46]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[44]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[47]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[48]

Drug(s) Transported By Breast cancer resistance protein (ABCG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[49]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[50]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[51]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[52]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[53]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[54]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[55]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[54]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[56]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[57]

Drug(s) Transported By Organic anion transporter 2 (SLC22A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[58]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[59]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[60]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[61]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[62]
Aciclovir	DMYLOVR	Genital herpes	1A94	Approved	[63]
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[64]
Entecavir	DM7VTQO	Hepatitis B virus infection	1E51.0	Approved	[65]
Theophylline	DMRJFN9	Bronchitis	CA20	Approved	[4]
Tetracycline	DMZA017	Acne vulgaris	ED80	Approved	[66]

Drug(s) Transported By Organic anion transporting polypeptide 1B3 (SLCO1B3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[68]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[69]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[70]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[68]
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[71]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[72]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[73]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[73]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[74]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[75]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[76]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[77]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[78]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[79]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[80]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[81]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[82]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[76]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[83]

Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[84]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[85]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[86]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[87]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[88]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[89]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[81]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[90]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[91]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[92]

Drug(s) Metabolized By Cytochrome P450 1A1 (CYP1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[93]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[94]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[95]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[96]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[90]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[97]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[98]
Riboflavin	DM8YMWE	Acne vulgaris	ED80	Approved	[99]
Mercaptopurine	DMTM2IK	Acute lymphoblastic leukaemia	2A85	Approved	[100]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[101]

Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[102]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[103]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[104]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[105]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[106]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[107]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[108]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[109]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[110]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[105]

Drug(s) Metabolized By Cytochrome P450 3A7 (CYP3A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[111]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[105]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[105]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[105]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[112]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[113]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[105]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[105]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[105]
Metronidazole	DMTIVEN	Abscess		Approved	[114]

Drug(s) Metabolized By Cytochrome P450 1B1 (CYP1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[115]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[95]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[90]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[98]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[116]
Vitamin A	DMJ2AH4	Night blindness	9D45	Approved	[117]
Caffeine	DMKBJWP	Allergic rhinitis	CA08.0	Approved	[118]
Melatonin	DMKWFBT	Depression	6A70-6A7Z	Approved	[119]
Theophylline	DMRJFN9	Bronchitis	CA20	Approved	[118]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[120]

Drug(s) Metabolized By Docosahexaenoic acid omega-hydroxylase (CYP4F11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[14]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[14]
Benzphetamine	DMIJATC	Obesity	5B81	Approved	[14]
Ethylmorphine	DM0YROF	Discovery agent	N.A.	Investigative	[14]

Drug(s) Affected By Nuclear protein 1 (NUPR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[121]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[122]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[17]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[123]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[122]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[122]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[124]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[122]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[125]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[17]

Drug(s) Affected By Inhibin beta E chain (INHBE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[122]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[123]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[122]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[122]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[124]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[122]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[126]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[122]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[127]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[17]

Drug(s) Affected By Acid ceramidase (ASAH1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[122]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[128]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[17]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[129]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[122]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[17]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[124]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[122]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[130]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[122]

Drug(s) Affected By Fibronectin type III domain-containing protein 4 (FNDC4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[122]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[122]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[122]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[122]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[122]
Haloperidol	DM96SE0	Delirium		Approved	[17]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[131]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[132]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[122]
Pentamidine	DMHZJCG	African trypanosomiasis	1F51	Approved	[122]

Drug(s) Affected By Protein DEPP1 (DEPP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[122]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[17]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[133]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[122]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[122]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[124]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[122]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[134]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[17]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[122]

Drug(s) Affected By Bile salt export pump (ABCB11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[135]
Ezetimibe	DM7A8TW	Atherosclerosis	BD40	Approved	[18]
Glipizide	DMZA5PQ	Diabetic complication	5A2Y	Approved	[18]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[136]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[135]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[18]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[137]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[135]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[138]
Nitrendipine	DM21C09	Hypertension	BA00-BA04	Approved	[135]

Drug(s) Affected By Protein c-Fos (FOS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[139]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[140]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[141]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[142]
Acebutolol	DM0TI4U	Hypertension	BA00-BA04	Approved	[141]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[143]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[144]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[145]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[146]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[147]

Drug(s) Affected By HLA class I histocompatibility antigen, alpha chain G (HLA-G)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[148]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[19]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[149]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[19]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[150]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[151]
Lisinopril	DMUOK4C	Chronic heart failure	BD1Z	Approved	[19]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[19]
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[19]
Pyrimethamine	DM5X7VY	Malaria	1F40-1F45	Approved	[19]

Drug(s) Affected By Misshapen-like kinase 1 (MINK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[148]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[152]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[132]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[153]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[154]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[155]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[156]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[157]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[158]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial 50S ribosomal RNA (Bact 50S rRNA)	TTUWYEA	NOUNIPROTAC	Binder	[3]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic anion transporter 2 (SLC22A7)	DT0OC1Q	S22A7_HUMAN	Substrate	[4]
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[5]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[6]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[7]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[8]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[9]
Cytochrome P450 1A1 (CYP1A1)	DE6OQ3W	CP1A1_HUMAN	Substrate	[10]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[11]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[12]
Cytochrome P450 1B1 (CYP1B1)	DE9QHP6	CP1B1_HUMAN	Substrate	[10]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[13]
Docosahexaenoic acid omega-hydroxylase (CYP4F11)	DEIZLTN	CP4FB_HUMAN	Substrate	[14]
Beta-glucuronidase (uidA)	DE7IQ34	A0A2A5L2J1_LACRH	Substrate	[15] , [16]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Acid ceramidase (ASAH1)	OT1DNGXL	ASAH1_HUMAN	Gene/Protein Processing	[17]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Gene/Protein Processing	[18]
Fibronectin type III domain-containing protein 4 (FNDC4)	OTOQK0WK	FNDC4_HUMAN	Gene/Protein Processing	[17]
HLA class I histocompatibility antigen, alpha chain G (HLA-G)	OTMLK1KN	HLAG_HUMAN	Gene/Protein Processing	[19]
Inhibin beta E chain (INHBE)	OTOI2NYG	INHBE_HUMAN	Gene/Protein Processing	[17]
Misshapen-like kinase 1 (MINK1)	OTKB0RA8	MINK1_HUMAN	Drug Response	[20]
Nuclear protein 1 (NUPR1)	OT4FU8C0	NUPR1_HUMAN	Gene/Protein Processing	[17]
Protein c-Fos (FOS)	OTJBUVWS	FOS_HUMAN	Gene/Protein Processing	[21]
Protein DEPP1 (DEPP1)	OTB36PHJ	DEPP1_HUMAN	Gene/Protein Processing	[17]
Vascular cell adhesion protein 1	OTP74K37	VCAM1_HUMAN	Gene/Protein Processing	[22]

References

• [1] Erythromycin FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1456).
• [3] A synthetic alanyl-initiator tRNA with initiator tRNA properties as determined by fluorescence measurements: comparison to a synthetic alanyl-elongator tRNA. Nucleic Acids Res. 1991 Oct 25;19(20):5749-54.
• [4] Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos. 2005 May;33(5):619-22.
• [5] Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin Pharmacol Ther. 2011 May;89(5):693-701.
• [6] ABCG2: a perspective. Adv Drug Deliv Rev. 2009 Jan 31;61(1):3-13.
• [7] Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
• [8] Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids. Pharm Res. 2009 May;26(5):1270-82.
• [9] Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. Br J Clin Pharmacol. 2003 Jan;55(1):86-93.
• [10] Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
• [11] Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metab Dispos. 1998 Nov;26(11):1053-7.
• [12] Differential regulation of CYP3A4 and CYP3A5 and its implication in drug discovery. Curr Drug Metab. 2017;18(12):1095-1105.
• [13] Helices F-G are important for the substrate specificities of CYP3A7. Drug Metab Dispos. 2007 Mar;35(3):484-92.
• [14] Expression and characterization of human cytochrome P450 4F11: putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):295-304.
• [15] Identification of Lactobacillus sakei genes induced during meat fermentation and their role in survival and growth. Appl Environ Microbiol. 2007 Apr;73(8):2522-31.
• [16] Degradation of various insecticides in cooked eggs during in vitro human digestion. Environ Pollut. 2018 Dec;243(Pt A):437-443.
• [17] Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
• [18] Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
• [19] Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
• [20] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [21] Liver toxicity of macrolide antibiotics in zebrafish. Toxicology. 2020 Aug;441:152501. doi: 10.1016/j.tox.2020.152501. Epub 2020 May 23.
• [22] The in vitro effects of quinupristin/dalfopristin, erythromycin and levofloxacin at low concentrations on the expression of different cell adhesion molecules on the surface of endothelial cells (Eahy926). Toxicology. 2006 Jan 20;218(1):30-8. doi: 10.1016/j.tox.2005.09.014. Epub 2005 Nov 16.
• [23] An examination of the differential sensitivity to ketolide antibiotics in ermB strains of Streptococcus pyogenes and Streptococcus pneumoniae. Curr Microbiol. 2004 Oct;49(4):239-47.
• [24] Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21.
• [25] Review of macrolides and ketolides: focus on respiratory tract infections. Drugs. 2001;61(4):443-98.
• [26] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [27] Depression of colony formation by human thymus-derived lymphocytes with rifampin and other antimicrobial agents. J Infect Dis. 1981 Jun;143(6):832-5.
• [28] Retapamulin inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells. Antimicrob Agents Chemother. 2007 Sep;51(9):3385-7.
• [29] The streptogramin antibiotics: update on their mechanism of action. Expert Opin Investig Drugs. 1998 Apr;7(4):591-9.
• [30] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [31] The protein synthesis inhibitors, oxazolidinones and chloramphenicol, cause extensive translational inaccuracy in vivo. J Mol Biol. 2002 Sep 13;322(2):273-9.
• [32] Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
• [33] Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
• [34] Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
• [35] Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
• [36] Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
• [37] Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
• [38] Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
• [39] Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
• [40] Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
• [41] Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
• [42] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [43] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [44] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [45] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [46] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [47] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [48] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [49] Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
• [50] Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
• [51] The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
• [52] Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
• [53] Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
• [54] Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
• [55] The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
• [56] Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
• [57] Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
• [58] Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol. 2003;146:95-158.
• [59] Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
• [60] Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
• [61] Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
• [62] Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82.
• [63] Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. Mol Pharmacol. 2008 Apr;73(4):1151-8.
• [64] A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
• [65] Human organic anion transporter 2 is an entecavir, but not tenofovir, transporter. Drug Metab Pharmacokinet. 2017 Feb;32(1):116-119.
• [66] Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76.
• [67] LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
• [68] Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
• [69] Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
• [70] Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
• [71] Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
• [72] Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
• [73] FDA Drug Development and Drug Interactions
• [74] Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004 Oct;311(1):139-46.
• [75] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [76] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [77] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [78] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [79] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [80] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [81] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [82] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [83] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [84] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [85] Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
• [86] Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
• [87] Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
• [88] PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
• [89] The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
• [90] The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
• [91] Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
• [92] Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
• [93] Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
• [94] Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
• [95] Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
• [96] Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7.
• [97] Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
• [98] A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
• [99] Disruption of endogenous regulator homeostasis underlies the mechanism of rat CYP1A1 mRNA induction by metyrapone. Biochem J. 1998 Apr 1;331 ( Pt 1):273-81.
• [100] Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
• [101] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [102] Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
• [103] Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
• [104] Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
• [105] Drug Interactions Flockhart Table
• [106] Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
• [107] Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
• [108] Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
• [109] Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
• [110] Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
• [111] The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
• [112] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [113] Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
• [114] The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
• [115] Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis. 1999 Aug;20(8):1607-13.
• [116] Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. Clin Ther. 2008 Jul;30(7):1283-9.
• [117] Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
• [118] Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos. 1997 May;25(5):617-22.
• [119] Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
• [120] Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther. 2001 Feb;296(2):537-41.
• [121] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [122] A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
• [123] In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Toxicol Sci. 2007 Sep;99(1):162-73.
• [124] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [125] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [126] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [127] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [128] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [129] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [130] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [131] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [132] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [133] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [134] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [135] Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
• [136] Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
• [137] Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
• [138] A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
• [139] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [140] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [141] Selection of drugs to test the specificity of the Tg.AC assay by screening for induction of the gadd153 promoter in vitro. Toxicol Sci. 2003 Aug;74(2):260-70. doi: 10.1093/toxsci/kfg113. Epub 2003 May 2.
• [142] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [143] Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
• [144] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [145] Methotrexate induces production of IL-1 and IL-6 in the monocytic cell line U937. Arthritis Res Ther. 2014 Jan 20;16(1):R17. doi: 10.1186/ar4444.
• [146] Simvastatin inhibits NOR-1 expression induced by hyperlipemia by interfering with CREB activation. Cardiovasc Res. 2005 Aug 1;67(2):333-41. doi: 10.1016/j.cardiores.2005.03.016. Epub 2005 Apr 21.
• [147] The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem. 2004 Jun 25;279(26):27008-16. doi: 10.1074/jbc.M403588200. Epub 2004 Apr 16.
• [148] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [149] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [150] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [151] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [152] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [153] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [154] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [155] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [156] Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. PLoS One. 2011;6(8):e23569.
• [157] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [158] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.